Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
OPKO Health, Inc. (NASDAQ: OPK) is a multinational biopharmaceutical and diagnostics company. This news page aggregates press releases and announcements related to OPKO’s pharmaceutical, diagnostics and collaboration activities, offering a focused view of how the company communicates business developments to the market.
Readers can find news about OPKO’s quarterly business highlights and financial results, as reported in its earnings press releases and accompanying conference call information. These updates typically summarize segment performance across pharmaceuticals and diagnostics, and describe notable transactions such as the sale of certain BioReference Health oncology and related clinical assets to Labcorp.
The news feed also reflects OPKO’s biopharmaceutical pipeline and research collaborations. Items include disclosures from ModeX Therapeutics, an OPKO Health company, on multispecific antibody programs like MDX2001 and MDX2004, as well as collaboration agreements with partners such as Regeneron Pharmaceuticals and Merck. In addition, OPKO reports on joint work with Entera Bio on oral GLP-1/glucagon and GLP-2 tablet candidates and on regulatory milestones for diagnostics such as the 4Kscore® Test.
Investors and observers can follow OPKO’s participation in healthcare investor conferences, where management holds one-on-one meetings and public discussions, as well as announcements about share repurchase authorizations and capital structure transactions. By reviewing this page regularly, users can see how OPKO presents its operational progress, collaborations and diagnostics initiatives over time.
OPKO Health, Inc. (NASDAQ: OPK) announces the retirement of Jon R. Cohen, M.D., as Executive Chairman and CEO of BioReference Laboratories. He will serve as an advisor until December 2022 and as a consultant for nine additional months. Craig Allen, previously President and COO, is appointed Interim CEO. Cohen, recognized for leading BioReference during the COVID-19 pandemic and establishing Scarlet Health, leaves a legacy of growth and innovation. Allen brings over 25 years of lab industry experience, aiming for long-term profitable growth.
OPKO Health reports its Q2 2022 financial results with consolidated revenues of $309.9 million, down from $442.4 million year-over-year. The company experienced an operating loss of $10.7 million, contrasted with an operating income of $5.6 million in Q2 2021. Significant highlights include the acquisition of ModeX Therapeutics for $300 million in OPKO stock and $85 million in milestone payments from Pfizer for the launch of NGENLA. Loss per share stood at $0.14, compared to $0.03 in the previous year. Cash and equivalents were at $210.5 million.
OPKO Health (NASDAQ: OPK) will report its operating and financial results for Q2 2022 on August 4, 2022, after U.S. markets close. The company will hold a conference call at 4:30 p.m. Eastern Time to discuss these results and provide financial guidance. Investors are encouraged to pre-register for easier access to the call. A replay of the conference call will be available until August 11, 2022. OPKO is focused on establishing industry-leading positions in rapidly growing markets through its innovative biopharmaceutical and diagnostics expertise.
OPKO Health, Inc. (NASDAQ: OPK) will participate in the 2022 Jefferies Healthcare Conference from June 8-10 in New York City. Management's fireside chat is scheduled for June 9 at 8:00 a.m. Eastern time, and it will be webcast live, with a replay available on OPKO’s website. This event highlights OPKO's commitment to engaging with investors and showcasing its innovative biopharmaceutical and diagnostics initiatives.
OPKO Health, Inc. (NASDAQ: OPK) reported its financial results for Q1 2022, revealing consolidated revenues of $329.2 million, down from $545.2 million in Q1 2021. The company incurred a net loss of $55.4 million, or $0.08 per share, compared to a net income of $31.1 million in the previous year. Key business highlights include the acquisition of ModeX Therapeutics for $300 million in OPKO stock and the sale of GeneDx to Sema4, which provided $150 million in cash proceeds. Notably, OPKO expects to receive $85 million in milestone payments from Pfizer in Q2 2022.
OPKO Health, Inc. (NASDAQ: OPK) has acquired ModeX Therapeutics for $300 million in OPKO common stock, significantly enhancing its product pipeline. Notable appointments include Dr. Elias Zerhouni as President and Vice Chairman, Dr. Gary Nabel as Chief Innovation Officer, and Alexis Borisy as a Board member. ModeX specializes in innovative immune therapies for cancer and infectious diseases using multi-specific antibody technologies. This acquisition aims to leverage synergies in OPKO's diagnostics and therapeutics portfolio, potentially improving patient outcomes and accelerating product development.
OPKO Health, Inc. (NASDAQ: OPK) will report its financial results for Q1 2022 on May 9, 2022, after U.S. market close. The company's senior management will discuss the results and provide financial guidance during a live conference call at 4:30 PM ET. Participants can pre-register for the call and access a webcast on OPKO's Investor Relations page. A replay will be available until May 16, 2022. For further information about OPKO's operations and market position, visit their official website.
GeneDx, Inc. has published research highlighting the importance of genomic data sharing for identifying gene-disease relationships. This initiative, facilitated through GeneMatcher, has resulted in over 200 new associations of disease-gene links in just three years. The findings were published in Human Mutation, demonstrating how collaboration between clinicians and researchers can accelerate diagnosis for rare diseases. GeneDx's extensive database of over 300,000 clinical exomes plays a crucial role in these developments, significantly impacting patient diagnostics and advancing precision medicine.
Saol Therapeutics has announced a collaboration with GeneDx to identify patients with Pyruvate Dehydrogenase Complex Deficiency (PDCD), a rare mitochondrial disease affecting fewer than 300 children annually in the U.S. The partnership aims to increase recruitment for a Phase 3 clinical trial testing dichloroacetate (DCA), which has Orphan Product designation from the FDA for congenital lactic acidosis. The trial is crucial as PDCD currently lacks FDA-approved treatments. Dr. Peter Stacpoole emphasizes the importance of the collaboration for effective patient recruitment.
OPKO Health, Inc. (NASDAQ: OPK) announced its fourth quarter 2021 financial results with total revenues of $401.3 million, down from $494.6 million in Q4 2020. The company reported a net loss of $73.8 million, or $0.11 per share, compared to net income of $32.3 million a year prior. Key highlights include NGENLA® receiving regulatory approvals in multiple countries and RAYALDEE® launched in Germany. OPKO has entered a definitive agreement for Sema4 to acquire GeneDx for a potential total consideration of $623 million.